

## PEER-REVIEW REPORT

**Name of journal:** Artificial Intelligence in Cancer

**Manuscript NO:** 66932

**Title:** Therapeutic tumor vaccines - a rising star to benefit cancer patients

**Reviewer's code:** 00502951

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** Canada

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-04-10

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-04-14 20:44

**Reviewer performed review:** 2021-04-21 19:32

**Review time:** 6 Days and 22 Hours

<b>Scientific quality</b>	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

General comments: This is a well-written and thoughtfully organized overview of the current status of the development of therapeutic tumor vaccines. The main types, tumor cell vaccines, dendritic cell vaccines, polypeptide vaccines, viral/bacterial vector vaccines, and nucleic acid vaccines are accurately described. Their advantageous features as well as impediments are discussed and the results emerging from recent and current clinical trials highlighted. Specific comments: 1. It would be good to comment on how could the current massive use of mRNA vaccines for covid-19 immunization influence further progress with the use of mRNA tumor vaccines. 2. In the References section, listing of the reference #32 is incomplete.